MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
ZTS stock logo

ZTS

Zoetis Inc.

$75.56
0.48
 (0.64%)
Exchange:  NYSE
Market Cap:  31.677B
Shares Outstanding:  478.128M
Delayed data
Calculate ZTS Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Drug Manufacturers – General
   
CEO:  Kristin C. Peck
Full Time Employees:  13800
Address: 
10 Sylvan Way
Parsippany
NJ
7054
US
Website:  https://www.zoetis.com
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/07 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue8,544,0009,256,0009,467,000
Gross Profit5,834,0006,396,0006,673,000
EBITDA3,685,0003,872,0004,069,000
Operating Income3,069,0003,392,0003,597,000
Net Income2,344,0002,486,0002,673,000

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets14,286,00014,237,00015,467,000
Total Liabilities9,295,0009,467,00012,136,000
Total Stockholders Equity4,997,0004,770,0003,331,000
Total Debt6,755,0006,744,000196,000
Cash and Cash Equivalents2,039,0001,985,0002,312,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow2,353,0002,953,0002,904,000
Capital Expenditure-732,000-655,000-621,000
Free Cash Flow1,621,0002,298,0002,283,000
Net Income2,344,0002,496,0002,673,000
Net Change in Cash-1,540,000-54,000325,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)11,482,474.146Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)11,964,252.475Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)11,637,500Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)5,192,035.061Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)5,409,880.967Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)5,262,133.166Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)4,093,254.981Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)4,317,431.602Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)4,165,391.484Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)2,892,079.210Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)3,013,424.233Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)2,931,125.416Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)9.390Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)9.730Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)9.220Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)13Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)2Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
9.256B  ?P/S
 (TTM)
: 
3.33
?Net Income
 (TTM)
: 
2.486B  ?P/E
 (TTM)
: 
12.51
?Enterprise Value
 (TTM)
: 
38.975B  ?EV/FCF
 (TTM)
: 
18.25
?Dividend Yield
 (TTM)
: 
2.73%  ?Payout Ratio
 (TTM)
: 
33.64%
?ROE
 (TTM)
: 
62.41%  ?ROIC
 (TTM)
: 
21.79%
?Net Debt
 (TTM)
: 
4.808B  ?Debt/Equity
 (TTM)
: 
2.86
?P/B
 (TTM)
: 
9.87  ?Current Ratio
 (TTM)
: 
3.15

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
10.97Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates ZTS intrinsic value between $74.34 – $166.84 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about ZTS valuation

Is Zoetis Inc. (ZTS) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Zoetis Inc. (ZTS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is ZTS a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ZTS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is ZTS’s P/E ratio?

You can see ZTS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for ZTS?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is ZTS a good long-term investment?

Whether ZTS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

ZTS

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.64
MARKETSnap

Trading Metrics:

Open: 75.86   Previous Close: 75.08
Day Low: 75.25   Day High: 76.99
Year Low: 71.47   Year High: 160.48
Price Avg 50: 82.91   Price Avg 200: 115.9
Volume: 4.435M   Average Volume: 7.089M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Zoetis Deadline: ZTS Investors with Losses in Excess of $100K Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit
05-07-2026 19:44
Zoetis Deadline: ZTS Investors with Losses in Excess of $100K Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit
ZOETIS DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ZTS
01-07-2026 17:43
ZOETIS DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zoetis Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ZTS
Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
04-06-2026 13:00
Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Bragar Eagel & Squire, P.C. Reminds Zoetis, Inc. Investors to Contact the Firm Before the July 27th Lead Plaintiff Deadline
10-07-2026 12:51
Bragar Eagel & Squire, P.C. Reminds Zoetis, Inc. Investors to Contact the Firm Before the July 27th Lead Plaintiff Deadline
ZTS FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ZTS
09-07-2026 18:05
ZTS FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Zoetis Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ZTS
ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm
01-06-2026 04:02
ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read